Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Common Equity (2022 - 2025)

Stoke Therapeutics has reported Common Equity over the past 4 years, most recently at $352.5 million for Q4 2025.

  • Quarterly results put Common Equity at $352.5 million for Q4 2025, up 53.9% from a year ago — trailing twelve months through Dec 2025 was $352.5 million (up 53.9% YoY), and the annual figure for FY2025 was $352.5 million, up 53.9%.
  • Common Equity for Q4 2025 was $352.5 million at Stoke Therapeutics, up from $308.1 million in the prior quarter.
  • Over the last five years, Common Equity for STOK hit a ceiling of $352.5 million in Q4 2025 and a floor of $140.3 million in Q1 2024.
  • Median Common Equity over the past 4 years was $226.7 million (2022), compared with a mean of $236.2 million.
  • Biggest five-year swings in Common Equity: plummeted 34.37% in 2024 and later soared 149.44% in 2025.
  • Stoke Therapeutics' Common Equity stood at $184.8 million in 2022, then decreased by 13.68% to $159.6 million in 2023, then soared by 43.53% to $229.0 million in 2024, then soared by 53.9% to $352.5 million in 2025.
  • The last three reported values for Common Equity were $352.5 million (Q4 2025), $308.1 million (Q3 2025), and $334.9 million (Q2 2025) per Business Quant data.